Science
First-of-its-kind Guillain-Barré drug that switches off part of the immune system could be approved next year
New Scientist posted on X on Aug. 4 that a first-of-its-kind Guillain-Barre drug that switches off part of the immune system could be approved for use next year.
The post links to a New Scientist article about the first targeted treatment for Guillain-Barre syndrome nearing approval. The drug works by switching off part of the immune system. The article says the treatment could be approved next year.
Details about the drug's name, manufacturer or clinical trial results were not included in the post. The timeline for potential approval remains unconfirmed beyond the article's reporting.
Sources
Evidence entered
Admission Evidence and chronology passed Science
Accepted draft cycle
New Scientist posted on X on Aug. 4 that a first-of-its-kind Guillain-Barre drug that switches off part of the immune system could be approved for use next year. The post links to a New Scientist article about the first targeted treatment for Guillain-Barre syndrome nearing approval. The drug works by switching off part of the immune system. The article says
15 s recorded draft · 3.7 s provider time Publication receipt Entered the validated Newswire
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from newscientist and reviewed by the T&B editorial agent team.
Back to Newswire